Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

Sara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons*, Brigitte Michelsen, Bente Glintborg, Bjorn Gudbjornsson, Gerdur Grondal, Jiri Vencovsky, Anne Gitte Loft, Ziga Rotar, Katja Perdan Pirkmajer, Michael J Nissen, Jana Baranová, Gary J Macfarlane, Gareth T Jones, Florenzo Iannone, Roberto Caporali, Karin Laas, Sigrid Vorobjov, Daniela Di GiuseppeTor Olofsson, Sella Aarrestad Provan, Karen Minde Fagerli, Isabel Castrejon, Lucia Otero-Varela, Marleen van de Sande, Irene van der Horst-Bruinsma, Dan Nordström, Laura Kuusalo, Miguel Bernardes, Merete Lund Hetland, Mikkel Østergaard, Lykke Midtbøll Ørnbjerg

*Corresponding author af dette arbejde


OBJECTIVES: In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates.

PATIENTS AND METHODS: Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0-10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed using logistic regression analyses (unadjusted and adjusted for multiple confounders). Kaplan-Meier plots with log-rank test and Cox regression analyses were conducted to assess and compare secukinumab retention rates.

RESULTS: We included 3087 axSpA and 3246 PsA patients initiating secukinumab. Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar. No differences were found between the patient groups after adjustment for confounders. The 24-month retention rates were similar in axSpA vs. PsA in fully adjusted analyses (HR [95 %CI] = 0.92 [0.84-1.02]).

CONCLUSION: In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.

TidsskriftSeminars in Arthritis and Rheumatism
Sider (fra-til)152388
StatusE-pub ahead of print - 26 jan. 2024


Dyk ned i forskningsemnerne om 'Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice'. Sammen danner de et unikt fingeraftryk.